Dr Reddy’s Laboratories and Hetero, along with other generic drug makers, enter into voluntary licensing agreements with Gilead Sciences to produce and distribute HIV drug Lenacapavir in India and 120 LMICs. Lenacapavir, which inhibits HIV at multiple stages, recently showed promising results in prevention trials.
Related Posts
Ant Group’s profit surge 193% in post-crackdown recovery
Ant Group witnessed a remarkable 193% profit surge in the June quarter, rebounding from a previous decline attributed to regulatory constraints. The company’s resurgence contributed […]
AO Smith acquires Pureit Business from HUL
Global water technology company AO Smith Corporation completed its acquisition of Pureit, the water purification business of HUL, for approximately $120 million in cash. This […]
SC cancels Byju’s 158 crore settlement with BCCI
The Supreme Court has annulled Byju’s Rs 158 crore settlement with the BCCI for sponsorship dues of the Indian cricket team, citing the payment’s dubious […]